HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Millar, A B Search for Related Content PubMed PubMed Citation Articles by Millar, A B

IL-10: another therapeutic target in idiopathic pulmonary fibrosis?

Correspondence to:
Correspondence to:
Dr A B Millar
Lung Research Group, Department of Clinical Science at North Bristol, University of Bristol Paul O’Gorman Lifeline Centre, Southmead Hospital, Westbury-on-Trym, Bristol BS10 5NB, UK; Ann.Millar@bristol.ac.uk

Keywords: interleukin 10; gene therapy; transforming growth factor ß; idiopathic pulmonary fibrosis

The first 150 words of the full text of this article appear below.

These are exciting and hopeful times for those involved in the treatment of idiopathic pulmonary fibrosis (IPF). Despite the ever expanding wealth of cellular and molecular biology, translation into clinical trials for IPF has been limited.¹ However, in the last 2 years results on three potential therapeutic agents have been published, albeit with limited benefit, with others imminent.^2–4 The study by Nakagome et al⁵ in this issue of Thorax gives further support to the concept of interleukin (IL)-10 as an additional biological therapeutic agent.

In the last 20 years the ability of the scientific community to analyse the biological interactions between cells has led to an information explosion. This has been exemplified by the analysis of cytokine (and growth factor) networks.⁶ Typically, the initial identification of a protein is followed by its receptor(s), its inhibition or induction by lipopolysaccaride and dexamethasone, and then a cascade of publications . . . [Full text of this article]